A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Regimens in Subjects With Hepatic Steatosis and Elevated Liver Stiffness

Trial Profile

A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Regimens in Subjects With Hepatic Steatosis and Elevated Liver Stiffness

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2017

At a glance

  • Drugs GS 0976 (Primary) ; GS 9674 (Primary) ; Selonsertib (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Adverse reactions; Proof of concept
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 17 Nov 2017 Planned number of patients changed from 110 to 120.
    • 01 Sep 2017 Planned End Date changed from 1 Mar 2018 to 1 May 2018.
    • 01 Sep 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top